梅花生物：增持主体计划增持公司股份不低于30375万元且不高于35015万元

Group 1 - The core point of the article is that Meihua Biological Technology Group Co., Ltd. announced a plan for its directors, senior management, and core management team members to buy back shares in the company, reflecting their confidence in the company's future development and long-term investment value [1] - The buyback plan will commence on January 14, 2026, and will last for a maximum of 12 months, with the total amount of shares to be purchased estimated between RMB 303.75 million and RMB 350.15 million, including transaction fees [1] - The purchase will be conducted through the secondary market using legally owned or self-raised funds, with no upper limit on the buyback price, which will be determined based on market conditions [1] Group 2 - The article also mentions a separate case involving Haili Biological, which experienced a ninefold increase in valuation due to an acquisition, but its valuation has since halved over eight months, raising concerns about its first major client, which is reportedly a company that has not yet been established [1]